Can engineered immune cells outsmart resistant blood cancers?
NCT ID NCT07758673
First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time
Summary
This early-stage trial is investigating whether a new type of CAR T-cell therapy, which targets a protein called BAFFR on cancer cells, can safely and effectively treat adults with B-cell acute lymphoblastic leukemia or B-cell lymphoblastic lymphoma that has returned or not responded to prior treatments. Participants' own T cells are collected, modified in the lab to recognize and attack cancer cells, and then infused back into the patient. The study aims to assess the treatment's safety, side effects, and potential to achieve remission.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BAFFR-targeting CAR T cells
- What this could lead to
- If successful, this could lead to a new treatment option for patients with B-cell acute lymphoblastic leukemia or lymphoma that has returned or not responded to standard therapies.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the treatment may not be effective or may cause significant side effects, including cytokine release syndrome or neurotoxicity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOBLASTIC LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
City of Hope at Irvine Lennar
Irvine, California, 92618, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Triple-Target CAR T-Cells offer new hope for tough blood cancers
- New drug cocktail shows promise for Hard-to-Treat leukemia
- Can a pill make CAR T-Cell therapy last longer?
- Experimental CAR t therapy targets tough leukemia in first human trial
- Leukemia treatment may erase vaccine protection—study tests if re-vaccination works
- Smart drug hunts down hidden leukemia cells